Q4 2024 Ajanta Pharma Ltd Earnings Call Transcript
Key Points
- Ajanta Pharma Ltd (BOM:532331) reported a 20% year-over-year increase in revenue for Q4 FY24, reaching INR1,054 crore.
- EBITDA for Q4 FY24 surged by 86% to INR278 crore, with an EBITDA margin of 26%.
- Profit after tax (PAT) for Q4 FY24 increased by 66% to INR203 crore.
- The company announced a buyback of equity shares at INR2,770 per share, with a total payout of INR351 crore.
- Ajanta Pharma Ltd (BOM:532331) achieved a cash conversion ratio of 67% and distributed INR642 crore as dividends, reflecting strong shareholder returns.
- The company faced technical issues during the earnings call, causing delays in uploading the list of highlights.
- Despite strong performance, the EBITDA margin guidance for FY25 remains flat at 28%, indicating potential cost pressures.
- The Red Sea crisis has increased transit times and freight costs, impacting operational efficiency.
- Price erosion in the US market remains a concern, with an estimated 8-10% decline for existing products.
- The institutional business in Africa is unpredictable and heavily reliant on procurement agency schedules, making future performance uncertain.
Gentlemen, good day and welcome to Ajanta Pharma Q4 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you and over to you sir.
Thank you. Good evening and welcome to all of you. With me, I have Mr. Rajesh Agrawal, Joint Managing Director, Mr. Arvind Agrawal, our CFO, Mr. Rajiv Agrawal, our A&D Finance and Investor Relation. Friends, we have a technical slag in uploading the list, so it just got uploaded short while back. My apologies for the same. But for the benefit of all the listeners who have joined, I will just read out the highlights of the performance of the quarter and then I will take you through the performance of each vertical for this quarter too.
So for Q4 FY24, our performance highlights as compared to the year-over-year are, revenue from the operations are at INR1,054 crore against INR82 crore up by 20%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
